MedTrace Logo

Metabolic Changes in Chronic HCV Patients Receiving DAAS

NCT04211844 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2020-01-02

No results posted yet for this study

Summary

Observational Study to check metabolic changes between two different hepatitis C antiviral medication groups. This study will evaluate the impact of different treatments on Serum lipid changes, fasting blood glucose and glycated hemoglobin . It will determine if changes are due to different Antiviral regimens or due to different Sustained virological response rates.

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

sofosbuvir plus daclatasvir

50 patients in the first group will receive 400 mg sofosbuvir plus daclatasvir 60 mg once daily for 12 weeks.

DRUG

Sofosbuvir plus Ledipasvir

50 patients in the second group will receive 400 mg sofosbuvir plus ledipasvir 90 mg (Harvoni) once daily for 12 weeks.

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Nehal Abdel Fattah, PharmB · Ain Shams University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2020-04-30
Completion
2020-04-30
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04211844 on ClinicalTrials.gov